128 related articles for article (PubMed ID: 35417384)
21. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
23. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.
Liu S; Staats P; Lee M; Alexander HR; Burke AP
Pathology; 2014 Dec; 46(7):604-9. PubMed ID: 25393250
[TBL] [Abstract][Full Text] [Related]
24. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
25. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
26. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
27. Diffuse intrapulmonary mesothelioma mimicking pulmonary lepidic adenocarcinoma: a rare case report and review of the literature.
RanYue W; ChunYan W; Likun H; LiPing Z; JieLu L; ZhengWei D
Diagn Pathol; 2023 May; 18(1):64. PubMed ID: 37194050
[TBL] [Abstract][Full Text] [Related]
28. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
30. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
Manur R; Lamzabi I
Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
[TBL] [Abstract][Full Text] [Related]
31. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review.
Yao DX; Shia J; Erlandson RA; Klimstra DS
Ultrastruct Pathol; 2004; 28(4):213-28. PubMed ID: 15693633
[TBL] [Abstract][Full Text] [Related]
32. The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.
Panjković M; Lovrenski A; Eri Z; Usaj SK; Tegeltija D; Krcedinac J
Vojnosanit Pregl; 2013 Nov; 70(11):1010-4. PubMed ID: 24397195
[TBL] [Abstract][Full Text] [Related]
33. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
34. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
35. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
Johansson L; Lindén CJ
Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
[TBL] [Abstract][Full Text] [Related]
36. [Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].
Lao I; Chen Q; Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):364-9. PubMed ID: 25208984
[TBL] [Abstract][Full Text] [Related]
37. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
38. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
39. Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature.
Demirag F; Unsal E; Tastepe I
Lung Cancer; 2007 Aug; 57(2):233-6. PubMed ID: 17363104
[TBL] [Abstract][Full Text] [Related]
40. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
